Display options
Cite
Chatzidionysiou K, Samoli E, Sfikakis PP, et al. Response to: 'Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou . Ann Rheum Dis. 2020;doi: 10.1136/annrheumdis-2020-218444.
Chatzidionysiou, K., Samoli, E., Sfikakis, P. P., & Tektonidou, M. G. (2020). Response to: 'Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou . Annals of the rheumatic diseases, . https://doi.org/10.1136/annrheumdis-2020-218444
Chatzidionysiou, Katerina, et al. "Response to: 'Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou ." Annals of the rheumatic diseases vol. (2020). doi: https://doi.org/10.1136/annrheumdis-2020-218444
Chatzidionysiou K, Samoli E, Sfikakis PP, Tektonidou MG. Response to: 'Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou . Ann Rheum Dis. 2020 Aug 04; doi: 10.1136/annrheumdis-2020-218444. Epub 2020 Aug 04. PMID: 32753416.
Copy Download .nbib Format: NLM
Share it on

Ann Rheum Dis. 2020 Aug 04; doi: 10.1136/annrheumdis-2020-218444. Epub 2020 Aug 04.

Response to: 'Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou .

Annals of the rheumatic diseases

Katerina Chatzidionysiou, Evangelia Samoli, Petros P Sfikakis, Maria G Tektonidou

Affiliations

  1. 1st Department of Propaedeutic and Internal Medicine, Joint Rheumatology Program, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Attica, Greece.
  2. Department of Hygiene, Epidemiology, and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  3. 1st Department of Propaedeutic and Internal Medicine, Joint Rheumatology Program, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Attica, Greece [email protected].

PMID: 32753416 DOI: 10.1136/annrheumdis-2020-218444

[No abstract available.]

Keywords: antibodies, antiphospholipid; biological therapy; lupus erythematosus, systemic

Conflict of interest statement

Competing interests: KC: has received consultant fees from AbbVie, Pfizer and Lilly. ES: none. PPS: has received fees from grants deposited to the Special Account for Research Funding (ELKE) of the Na

Publication Types